Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» FDA panel overwhelmingly says risks of J&J ovarian cancer drug outweigh potential benefits
FDA panel overwhelmingly says risks of J&J ovarian cancer drug outweigh potential benefits
FDA panel overwhelmingly says risks of J&J ovarian cancer drug outweigh potential benefits
Submitted by
admin
on July 16, 2009 - 8:52am
Source:
Yahoo/AP
News Tags:
FDA
JNJ
ovarian cancer
Yondelis
Headline:
FDA panel overwhelmingly says risks of J&J ovarian cancer drug outweigh potential benefits
Do Not Allow Advertisers to Use My Personal information
